Fitusiran is an investigational RNA interference (RNAi) therapeutic developed by Alnylam Pharmaceuticals in collaboration with Sanofi Genzyme.

GSK has struck a deal to buy CMG1A46 from Chimagen Biosciences to enhance its immunology portfolio.

LRallybio has received approval for clinical trial applications to conduct a Phase 2 study of RLYB212 in expectant mothers who are at increased risk of alloimmunization and FNAIT.

Immunome reveals strong preclinical results showcasing significant anti-tumor effects of IM-1021.

Aro Biotherapeutics has begun recruiting participants for a Phase 1b study of ABX1100 in individuals with Late-Onset Pompe Disease (LOPD).

Clover reveals encouraging clinical results for its RSV vaccine SCB-1019 when compared to GSK’s AREXVY.

According to statistical data, the miRNA drug market was estimated at approximately $160.5 million in 2017, with an expected compound annual growth rate (CAGR) of 18.6%.

Monte Rosa Therapeutics has signed a worldwide licensing deal with Novartis to promote VAV1-targeted molecular glue degraders that modulate T and B cells.

Merck and Moderna have begun a Phase 3 study to assess V940 (mRNA-4157) with KEYTRUDA® (pembrolizumab).

Lilly’s mirikizumab is the first and only IL23p19 antagonist to provide long-term safety and efficacy data over several years for ulcerative colitis and Crohn’s disease.

AstraZeneca’s Fasenra (benralizumab) has received approval in the EU as a supplementary therapy for adults dealing with relapsing or refractory eosinophilic granulomatosis with polyangiitis.

Celldex Reports Barzolvolimab Successfully Achieved All Main and Secondary Goals with Strong Statistical Significance in Positive Phase 2 Trial for Chronic Inducible Urticaria.